ACR Convergence 2021

November 5-9, 2021. All Virtual.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 0529

COPA Syndrome-associated Mutations in Lung Transplant Recipients for Interstitial Lung Disease
Abstract Number: 0806

Coping with Recent-onset Rheumatoid Arthritis (RA): Validation of the Coping with Health Injuries and Problems (CHIP) Questionnaire in a Longitudinal Cohort
Abstract Number: 0318

Correlation Between Prognostic Nutritional Index and Primary Sjögren’s Syndrome Disease Activity
Abstract Number: 0635

Correlation Between Provider Documentation and Patient Experience with Contraceptive Counseling in an Academic Rheumatology Practice
Abstract Number: 0634

Correlation Between the Functional Component of the Multidimensional Health Assessment Questionnaire (FN), Modified Health Assessment Questionnaire (MHAQ), Health Assessment Questionnaire II (HAQ-II) and a Single Functional Question (PF) in Patients with Rheumatic Disease
Abstract Number: 0474

Correlation of Fibromyalgia Survey Questionnaire and Quantitative Sensory Testing Among Patients with Active Rheumatoid Arthritis
Abstract Number: 0175

Correlation of Subclinical Synovitis with Juvenile Idiopathic Arthritis Outcome Measurements
Abstract Number: 1812

Correlations Between Reductions in Fatigue Severity and Improvements in Physical Function and Clinical Response in Patients with Psoriatic Arthritis: Results from the Phase 3 DISCOVER Program
Abstract Number: 0465

Cost-effectiveness of Treatment Strategies Involving Arthroscopic Partial Meniscectomy and Physical Therapy for Degenerative Meniscal Tear
Abstract Number: 1129

Cost-effectiveness of Weight Loss Interventions Prior to Total Knee Replacement for Patients with Advanced Knee Osteoarthritis and Class III Obesity
Abstract Number: 1085

COVID 19 Infection in Patients with Rheumatic Immune-mediated Diseases in a Single University Hospital: Matched Case-control Study
Abstract Number: 1084

COVID-19 Among Patients with Inflammatory Arthropathies Participating in the RHUMADATA Clinical Database and Registry
Abstract Number: 0882

COVID-19 Impact Among Patients with Systemic Lupus Erythematosus
Abstract Number: 1671

COVID-19 in Patients with Rheumatoid Arthritis Compared to Patients with Osteoarthritis During the Pandemic in New York City
Abstract Number: 1452

COVID-19 Infection Among Autoimmune/Auto-inflammatory Rheumatic Disease Patients: Data from an Observational Study

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].